Skip to content

Survey of combination of Memantine and methylphenidate among treatment the children with ADHD(Attention-deficit/hyperactivity disorder)

Survey of combination of Memantine and methylphenidate among treatment the children with ADHD(Attention-deficit/hyperactivity disorder)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201208058317N2
Enrollment
20
Registered
2012-12-06
Start date
2012-10-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder. Disturbance of activity and attention

Interventions

Intervention 1: The first group is given Methylphenidate and Memantine with the dose of 10 mg per day. Methylphenidate, starts to the amount of approximately 0.3 mg per kg of body weight in both morni
Treatment - Drugs
Placebo
The second group is given Methylphenidate and placebo . Methylphenidate, starts to the amount of approximately 0.3 mg per kg of body weight in both morning and afternoon, and increases based on side e
The first group is given Methylphenidate and Memantine with the dose of 10 mg per day. Methylphenidate, starts to the amount of approximately 0.3 mg per kg of body weight in both morning and afternoon

Sponsors

Research deputy of Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1-Having diagnostic criteria based on the revised text of the fourth statistical detection guide to identify mental disorders and tests Conners (Test for diagnosing hyperactivity disorder and it’s grading), In this study, cases of moderate and severe impairment (score greater than or equal to 20 conners) are studied. 2-Age between 6 to 12 years. 3-Obtaining informed consent from parents. Exclusion criteria: 1-Other psychiatric disorder based on a criteria based DSM IV_TR 2-Mental retardation. 3-Having a history of seizures. 4-Any medical problems, including the use of beta blockers and methylphenidate such as asthma, cardiovascular problems, diabetes, history of allergy to drugs, the tic

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The amount of improvement of ADHD symptoms. Timepoint: Before the intervention, 1th, 2th, 3th and 4th weeks after intervention. Method of measurement: Conners test.

Secondary

MeasureTime frame
Side effects. Timepoint: Before the intervention, 1th, 2th, 3th and 4th weeks after intervention. Method of measurement: Onset of symptoms based on parents day comment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDavood mohammadbeigi

Ahwaz Jondi Shapur University of Medical Sciences

Dr.davood.mohammadbeigi@gmail.com+98 85 1334 8261

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026